Member Info for Jarv55

http://www.midatechpharma.com/uploads/investor_files/Shareholder%20Circular%20and%20Notice%20of%20General%20Meeting%20to%20be%20held%20on%2015%20October%202018.pdf

It is on the end which isn't published here

They could do with updating the share holder register http://www.midatechpharma.com/shareholder-information

Reading between the lines I don't think the funding is going to be a problem.

The Board believe that if possible it would be preferable to establish a clear development pathway for MTD201 (as discussed below) prior to the fundraise. On the basis of a clear development plan (see options 1 and 2 below) the Company has a number of indications of equity support.

4 million market cap is a joke.

PP their is a huge valuation disconnect but that is due to L and G selling and the cash situation. But they are just waiting for the fda approval to find out how much cash they are going to need. I think they have planned for a lengthy process and that is why they are licensing out. Whatever way you look at it when this gets approval it is a sitting duck. Can't see Novataris allowing a product that could be better than theirs to stay on the market. I think they will want control of it.

It is very interesting that they are buying in America. Now if this deal is done for the finance what will the benchmark be for the price the Uk market or the Us?

Sillybagger nice back test there on your chart.

https://asia.nikkei.com/Business/Indian-and-Chinese-drugmakers-dominate-Asia-power-ranking

From Advfn
Zen12
31 Aug '18 - 22:09 - 166 of 244
0 0 0
But they forgot the other big development tech Q-Sphera!
‘ Second, this study is a major validation and inflection point for Midatech's Q-Sphera™ technology establishing it as an exciting new sustained-release delivery platform, to administer pharmaceuticals safely, conveniently and effectively, without a burst phenomenon, and over a prolonged period. After five years of development, we are delighted to have achieved positive first-in-human data. We look forward to unlocking the full potential of our MTD201 programme as well as the Q-Sphera platform, both for Midatech and for our partners looking to capt

20 December 2018

Midatech Pharma PLC

("Midatech", "Company" or "Group")

Midatech Announces Q-Spheraâ„¢ Microsphere Technology Partnership

- Collaboration agreed with major regional pharmaceutical company

- Midatech's leading technology will be used in development and evaluation with a key clinical program

- Further validates Q-Spheraâ„¢ sustained release drug delivery technology

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the R&D company focused on delivering innovative oncology and rare disease products to patients, today announces an agreement with a major regional corporation ("the Partner"), in which the Partner will evaluate Midatech's Q-Spheraâ„¢ microsphere sustained release technology for use with the Partner's materials.

Under the collaboration agreement, the Partner will conduct a feasibility program using Midatech's Q-Spheraâ„¢ technology. No financial terms have been disclosed.

The agreement follows the positive clinical 'proof-of-concept' in August this year for Q-Spheraâ„¢ as a sustained release drug platform in the MTD201 first-in-human study. This study was a key inflection and validation point for both the Q-Spheraâ„¢ technology, as well as its application in a therapeutic product MTD201 for carcinoid cancer and acromegaly.

Q-Spheraâ„¢ is the next generation micro-encapsulation and polymer-depot sustained release (SR) drug delivery platform developed by Midatech using a novel and disruptive printing-based process, with significant and distinct advantages over conventional technologies. From a manufacturing perspective Q-Spheraâ„¢ is an improved precise, scalable, efficient, and environmentally friendly microparticle manufacturing platform. From a clinical profile perspective it ensures homogenous microparticles that release active drug compounds into the body in a linear, well controlled and predictable manner over an extended period of time. Finally, from a convenience perspective Q-Sphera allows simpler and quicker reconstitution, improved injectability and less painful injections due to the smaller needle size required.

The global controlled release market size is in the order of $32bn, and the current market for sustained release microsphere products is approximately $6bn pa1 which includes blockbuster drugs for oncology, hormonal disorders, autoimmune diseases, various mental health disorders, alcohol/ drug dependence and pain management.

http://www.lse.co.uk/share-regulatory-news.asp?shareprice=MTPH&ArticleCode=5yfuc2pg&ArticleHeadline=Completion_of_Midatech_Pharma_US_Sale

LoveScotland its a bargain down here was £6 in the summer

Also interesting is the volume on the 10th in the Us http://www.stockhouse.com/companies/quote?symbol=mtp

Worth a read http://www.evaluate.com/vantage/articles/interviews/midatech-hopes-find-golden-touch-new-focus

Few nice buys there.

Rns is on Vox

Pp don't know why, it's not on lse either.

Bid is rising 6.15 to sell order filling?

No they have gone under 3%